No products in the cart.
CB1/CNR1: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It’s the GeneMedi’s summary page for Target/Biomarker Introduction of CB1/CNR1. The page also collects GeneMedi’s different modalities and formats products for CB1 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the CB1 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This gene encodes one of two cannabinoid receptors. The cannabinoids, principally delta-9-tetrahydrocannabinol and synthetic analogs, are psychoactive ingredients of marijuana. The cannabinoid receptors are members of the guanine-nucleotide-binding protein (G-protein) coupled receptor family, which inhibit adenylate cyclase activity in a dose-dependent, stereoselective and pertussis toxin-sensitive manner. The two receptors have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. Multiple transcript variants encoding two different protein isoforms have been described for this gene. [provided by RefSeq, May 2009]
|
Target ID |
GM-T76685
|
|
Target Name |
CB1
|
|
Gene ID |
1268
|
|
Gene Official Name |
CNR1
|
|
Gene Alias |
CANN6, CB-R, CB1, CB1A, CB1K5, CB1R, CNR
|
|
Protein Sub-location |
Transmembrane Protein
|
|
Category |
Therapeutics Target, INN Index
|
Pre-made CB1-specific INN-index biosimilar (antibody&conjugates)-Nimacimab
Anti-CB1 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Filters
Sort results
Reset
Apply
Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Order |
|---|---|---|---|---|---|---|
Pre-Made Nimacimab biosimilar, Whole mAb, Anti-CNR1/CB1 Antibody: Anti-CANN6/CB-R therapeutic antibody |
Nimacimab |
NA |
CNR1 |
Whole mAb |
Anti-CNR1/ CB1/ CANN6 antibody for FACS & in-vivo assay| GMab
Pre-made anti-CB1 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CB1 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Filters
Sort results
Reset
Apply
Cat No. | Antibody Name | Format | Classified by tag | Order
|
|---|---|---|---|---|
Anti-CB1/CNR1 monoclonal antibody |
mab |
FACS/Biofunctional Antibody, Therapeutics Target antibody |
